Attached files
file | filename |
---|---|
EX-99.1 - PRESENTATION - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
Exhibit 99.2
Cellular Biomedicine Group (CBMG) Hosts R&D Showcase and
Provides Updates to Clinical Programs
GAITHERSBURG, MD and SHANGHAI, China, July 13, 2020
– Cellular Biomedicine Group, Inc. (Nasdaq: CBMG)
(“CBMG” or the “Company”), a
biopharmaceutical firm engaged in the drug development of
immunotherapies for cancer and stem cell therapies for degenerative
diseases, provided an overview and update of clinical and
pre-clinical programs currently being researched and
developed.
The
Company is currently conducting the following studies:
Immuno-oncology
●
Anti-BCMA CAR
targeting Multiple Myeloma (MM)
●
Anti-CD19/CD20
BiCAR targeting NHL
●
AFP TCR-T targeting
hepatocellular carcinoma (HCC)
●
TIL1 (combo w/
anti-PD-1) targeting non-small cell lung cancer (NSCLC) –
Pre-clinical
Anti-BCMA
CAR, Anti-CD19/CD20 BiCAR, and TCR clinical studies up to date are
conducted through IIT (investigator-initiated trial).
Regenerative - Human Adipose Mesenchymal Progenitor Cells
(haMPC)
●
ReJoin® Autologous
therapy for Knee Osteoarthritis (KOA) – Phase II
●
AlloJoin®
Allogenic therapy for KOA – Phase II
AlloJoin®
and Re-Join® were both
approved for Phase 2 clinical trial by the Center for Drug
Evaluation (CDE) in 2019.
The
presentation included an overview from CEO and CFO, Tony (Bizuo)
Liu, an update on the clinical pipelines by CSO Dr. Yihong Yao and
Head of Development & Strategy Dr. Michael
Humphries.
“We are pleased to provide an overview of the development
work we are undertaking at CBMG. Our goal is to showcase the
various technology platforms and the current status of each of
those platforms. We are cautiously optimistic about our targets,
but our optimism has been bolstered by the preliminary outcomes of
the clinical data thus far,” said Tony (Bizuo) Liu, CEO and
CFO of CBMG. Mr. Liu added “The COVID-19 pandemic
has delayed enrollment and
infusion of clinical trial patients, however we
believe that we are now back to full capacity and continue to
execute our vision to deliver safe and effective drugs to patients
suffering from cancer and degenerative
diseases.”
A copy
of the presentation and transcript will be available on the Company
website at: https://www.cellbiomedgroup.com/investor-relations/presentations?lang=en
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China using products from its
integrated GMP laboratory. The Company’s GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. Its Shanghai facility includes a “Joint Laboratory
of Cell Therapy” with GE Healthcare and a “Joint Cell
Therapy Technology Innovation and Application Center” with
Thermo Fisher Scientific. These partnerships focus on improving
manufacturing processes for cell therapies. CBMG currently has
ongoing CAR-T Phase I clinical trials in China. The China NMPA
(formerly CFDA) approved the Company’s IND application for a
Phase II trial for AlloJoin®, CBMG’s
“Off-the-Shelf” allogenic haMPC therapy for the
treatment of Knee Osteoarthritis (KOA), and has accepted the
Company’s IND application for a Phase II trial for
ReJoin® autologous haMPC therapy for the treatment of KOA. The
NMPA has also accepted CBMG’s dossier for an IND application
for clinical trials of anti-BCMA CAR-T. CBMG is included in the
broad-market Russell 3000® Index the small-cap Russell
2000® Index and the Loncar China BioPharma index. To learn
more about CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
specific activities, and other statements that are not descriptions
of historical facts, including our statements regarding enrollment
of clinical trial patients and expectations relating to the
development, safety and efficacy of our drugs, may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in CBMG’s reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
including risks relating to the impact of the COVID-19 pandemic on
our operations, including risks associated with the evolving
COVID-19 pandemic and actions taken in response to it. Generally,
the words “believes,” “anticipates,”
“may,” “will,” “should,”
“could,” “expect,” “plans,”
“intend,” “estimate,”
“projects,” “presents,”
“potential,” “continue” and similar
expressions or the negative thereof or comparable terminology are
intended to identify forward-looking statements. These statements
reflect our current views with respect to future
events or
to our future activities and involve known and unknown risks,
uncertainties and other factors which may cause our actual
activities, actions or achievements to be materially different from
any future activities, actions or achievements expressed or implied
by the forward-looking statements. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements.
Company/Investor Contact:
Derrick
C. Li
Head of
Strategy and Investor Relations, CBMG
Phone:
917-717-0994
Email:
derrick.li@cellbiomedgroup.com